β-Amyloid Cancer Research Results
β-Amyloid, β-Amyloid Fibrils: Click to Expand ⟱
| Source: |
| Type: |
Amyloid-β (Aβ) fibrils are the main component of amyloid plaques that develop in brain tissue of Alzheimer's disease (AD) patients.
|
Scientific Papers found: Click to Expand⟱
| - |
Review, |
Nor, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*neuroP↑, A number of studies have reported that baicalein has potent neuroprotective properties under in vitro as well as in vivo systems
*ROS↓, Baicalein effectively prevents Alzheimer's and Parkinson's diseases by reducing oxidative stress, inhibiting aggregation of disease-specific amyloid proteins,
*β-Amyloid↓,
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
Stroke, |
NA |
|
|
|
- |
Review, |
IBD, |
NA |
|
|
|
- |
Review, |
Arthritis, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
cardioP↑, cardioprotective activities.
Inflam↓, Decreasing the accumulation of inflammatory mediators and improving cognitive function
cognitive↑,
*hepatoP↑, Decreasing inflammation, reducing oxidative stress, regulating the metabolism of lipids, and decreasing fibrosis, apoptosis, and steatosis are their main hepatoprotective mechanisms
*ROS?, Reducing oxidative stress and protecting the mitochondria to inhibit apoptosis are proposed as hepatoprotective mechanisms of baicalin in NAFLD
*SOD↑, Baicalin could reduce the levels of ROS and fatty acid-induced MDA, and increase superoxide dismutase (SOD) and glutathione amounts compared to the control.
*GSH↑,
*MMP↑, Moreover, baicalin could partially restore mitochondrial morphology and increase ATP5A expression and mitochondrial membrane potential (Gao et al., 2022).
*GutMicro↑, After baicalein treatment, a remodelling in the overall structure of the gut microbiota was observed
ChemoSen↑, Besides, a combination of baicalin and doxorubicin could elevate the chemosensitivity of MCF-7 and MDA-MB-231 breast cancer cells
*TNF-α↓, Baicalin can protect cardiomyocytes from hypoxia/reoxygenation injury by elevating the SOD activity and anti-inflammatory responses through reducing TNF-α, enhancing IL-10 levels, decreasing IL-6, and inhibiting the translocation of NF-κB to the nucl
*IL10↑,
*IL6↓,
*eff↑, Studies show that baicalin and baicalein may be effective against IBD by suppressing oxidative stress and inflammation, and regulating the immune system.
*ROS↓,
*COX2↓, baicalein can improve the symptoms of ulcerative colitis by lowering the expression of pregnane X receptor (PXR), (iNOS), (COX-2), and caudal-type homeobox 2 (Cdx2), as well as the NF-κβ and STAT3
*NF-kB↓,
*STAT3↓,
*PGE2↓, Administration of baicalin (30-90 mg/kg) could decrease the levels of prostaglandin E2 (PEG2), myeloperoxidase (MPO), IL-1β, TNF-α, and the apoptosis-related genes including Bcl-2 and caspase-9
*MPO↓,
*IL1β↓,
*MMP2↓, Rheumatoid arthritis RA mouse model by supressing relevant proinflammatory cytokines such as IL-1b, IL-6, MMP-2, MMP-9, TNF-α, iNOS, and COX-2)
*MMP9↓,
*β-Amyloid↓, Alzheimer’s disease (AD) : reduce β-amyloid and trigger non-amyloidogenic amyloid precursor proteins.
*neuroP↑, For instance, administration of baicalin orally for 14 days (100 mg/kg body weight) exhibited neuroprotective effects on pathological changes and behavioral deficits of Aβ 1–42 protein-induced AD in vivo.
*Dose↝, administration of baicalin (500 mg/day, orally for 12 weeks) could improve the levels of total cholesterol, TGs, LDLC and apolipoproteins (APOs), and high-sensitivity C-reactive protein (hs-CRP) in patients with rheumatoid arthritis and coronary arte
*BioAv↝, the total absorption of baicalin depends on the activity of intestinal bacteria to convert baicalin to baicalein as the first step.
*BioAv↝, Kidneys, liver, and lungs are the main organs in which baicalin accumulates the most.
*BBB↑, Baicalin and baicalein can pass through the blood brain barrier (BBB)
*BDNF↑, mechanism of action for baicalein is illustrated in Figure 3. Activation of the BDNF/TrkB/CREB pathway, inhibition of NLRP3/Caspase-1/GSDMD pathway,
*β-Amyloid↓, Aβ amyloid fibril formation
*cognitive↑,
*motorD↑, RMF improves motor and exploration abilities in
APP/PS1 mice
*ROS↓, RMF reduces oxidative stress in APP/PS1 mouse brains and lipid deposition in the liver
*memory↑, RMF significantly alleviates spatial memory impairments in APP/PS1 mice
*Aβ?, 0.4 T RMF inhibits Aβ amyloid fibril formation in vitro
*hepatoP↑, Apart from the hepatoprotective nature, which is mainly due to its antioxidant and tissue regenerative properties,
*neuroP↑, Silymarin has recently been reported to be a putative neuroprotective agent against many neurologic diseases including Alzheimer's and Parkinson's diseases, and cerebral ischemia
*ROS↓, capacity to inhibit oxidative stress in the brain,
*β-Amyloid↓, additional advantages by influencing pathways such as β‐amyloid aggregation, inflammatory mechanisms, cellular apoptotic machinery, and estrogenic receptor mediation.
*Inflam↓,
*Aβ↓, Silymarin on inhibition of Aβ fibril formation and aggregation in animal and cellular models of AD
*NF-kB↓, By inhibiting the production of inflammatory agents such as NF‐κB, TNF‐α, TNF‐β, iNOS, NO, COX, Silymarin impedes neuroinflammation
*TNF-α↓,
*TNF-β↓,
*iNOS↓,
*NO↓,
*COX2↓,
Showing Research Papers: 1 to 4 of 4
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4
Pathway results for Effect on Cancer / Diseased Cells:
Immune & Inflammatory Signaling ⓘ
Inflam↓, 1,
Drug Metabolism & Resistance ⓘ
ChemoSen↑, 1,
Functional Outcomes ⓘ
cardioP↑, 1, cognitive↑, 1,
Total Targets: 4
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
GSH↑, 1, MPO↓, 1, ROS?, 1, ROS↓, 4, SOD↑, 1,
Mitochondria & Bioenergetics ⓘ
MMP↑, 1,
Cell Death ⓘ
iNOS↓, 1,
Proliferation, Differentiation & Cell State ⓘ
STAT3↓, 1,
Migration ⓘ
MMP2↓, 1, MMP9↓, 1,
Angiogenesis & Vasculature ⓘ
NO↓, 1,
Barriers & Transport ⓘ
BBB↑, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 2, IL10↑, 1, IL1β↓, 1, IL6↓, 1, Inflam↓, 1, NF-kB↓, 2, PGE2↓, 1, TNF-α↓, 2, TNF-β↓, 1,
Synaptic & Neurotransmission ⓘ
BDNF↑, 1,
Protein Aggregation ⓘ
Aβ?, 1, Aβ↓, 1, β-Amyloid↓, 4,
Drug Metabolism & Resistance ⓘ
BioAv↝, 2, Dose↝, 1, eff↑, 1,
Clinical Biomarkers ⓘ
GutMicro↑, 1, IL6↓, 1,
Functional Outcomes ⓘ
cognitive↑, 1, hepatoP↑, 2, memory↑, 1, motorD↑, 1, neuroP↑, 3,
Total Targets: 35
Scientific Paper Hit Count for: β-Amyloid, β-Amyloid Fibrils
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:571 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page